Quadruple Versus Triple Combination Antiretroviral Therapies for Treatment Naive People with HIV: Systematic Review and Meta-analysis of Randomised Controlled Trials

Overview

Journal BMJ

Specialty General Medicine

Date 2019 Jul 10

PMID 31285198

Citations 16

Authors

Qi Feng

Aoshuang Zhou

Huachun Zou

Suzanne Ingle

Margaret T May

Weiping Cai

Chien-Yu Cheng

Zuyao Yang

Jinling Tang

Affiliations

Soon will be listed here.

Abstract

Objective: To evaluate the effects of four drug (quadruple) versus three drug (triple) combination antiretroviral therapies in treatment naive people with HIV, and explore the implications of existing trials for clinical practice and research.

Design: Systematic review and meta-analysis of randomised controlled trials.

Data Sources: PubMed, EMBASE, CENTRAL, Web of Science, and the Cumulative Index to Nursing and Allied Health Literature from March 2001 to December 2016 (updated search in PubMed and EMBASE up to June 2018); and reference lists of eligible studies and related reviews.

Study Selection: Randomised controlled trials comparing quadruple with triple combination antiretroviral therapies in treatment naive people with HIV and evaluating at least one effectiveness or safety outcome.

Review Methods: Outcomes of interest included undetectable HIV-1 RNA, CD4 T cell count, virological failure, new AIDS defining events, death, and severe adverse effects. Random effects meta-analyses were conducted.

Results: Twelve trials (including 4251 people with HIV) were eligible. Quadruple and triple combination antiretroviral therapies had similar effects on all relevant effectiveness and safety outcomes, with no point estimates favouring quadruple therapy. With the triple therapy as the reference group, the risk ratio was 0.99 (95% confidence interval 0.93 to 1.05) for undetectable HIV-1 RNA, 1.00 (0.90 to 1.11) for virological failure, 1.17 (0.84 to 1.63) for new AIDS defining events, 1.23 (0.74 to 2.05) for death, and 1.09 (0.89 to 1.33) for severe adverse effects. The mean difference in CD4 T cell count increase between the two groups was -19.55 cells/μL (-43.02 to 3.92). In general, the results were similar, regardless of the specific regimens of combination antiretroviral therapies, and were robust in all subgroup and sensitivity analyses.

Conclusion: In this study, effects of quadruple combination antiretroviral therapy were not better than triple combination antiretroviral therapy in treatment naive people with HIV. This finding lends support to current guidelines recommending the triple regimen as first line treatment. Further trials on this topic should be conducted only when new research is justified by adequate systematic reviews of the existing evidence. However, this study cannot exclude the possibility that quadruple cART would be better than triple cART when new classes of antiretroviral drugs are made available.

Citing Articles

Liver Transplantation in People Living with HIV: Still an Experimental Procedure or Standard of Care?.

Lynch E, Russo F Life (Basel). 2023; 13(10).

PMID: 37895356 PMC: 10608432. DOI: 10.3390/life13101975.

Current ART, determinants for virologic failure and implications for HIV drug resistance: an umbrella review.

SeyedAlinaghi S, Afsahi A, Moradi A, Parmoon Z, Habibi P, Mirzapour P AIDS Res Ther. 2023; 20(1):74.

PMID: 37884997 PMC: 10604802. DOI: 10.1186/s12981-023-00572-6.

The future of evolutionary medicine: sparking innovation in biomedicine and public health.

Natterson-Horowitz B, Aktipis A, Fox M, Gluckman P, Low F, Mace R Front Sci. 2023; 1.

PMID: 37869257 PMC: 10590274. DOI: 10.3389/fsci.2023.997136.

Efficacy and safety of Chinese patent medicine compound preparation combined with routine treatment in vitiligo: A Bayesian network meta-analysis.

Wang J, Wang D, Si G Medicine (Baltimore). 2023; 102(41):e35327.

PMID: 37832097 PMC: 10578774. DOI: 10.1097/MD.0000000000035327.

RECOVER identifies synergistic drug combinations in vitro through sequential model optimization.

Bertin P, Rector-Brooks J, Sharma D, Gaudelet T, Anighoro A, Gross T Cell Rep Methods. 2023; 3(10):100599.

PMID: 37797618 PMC: 10626197. DOI: 10.1016/j.crmeth.2023.100599.

References

Kirk O, Katzenstein T, Gerstoft J, Mathiesen L, Nielsen H, Pedersen C . Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: a randomized trial. AIDS. 1999; 13(1):F9-16. DOI: 10.1097/00002030-199901140-00002. View

Jordan R, Gold L, Cummins C, Hyde C . Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy. BMJ. 2002; 324(7340):757. PMC: 100314. DOI: 10.1136/bmj.324.7340.757. View

Fischl M, Ribaudo H, Collier A, Erice A, Giuliano M, Dehlinger M . A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. J Infect Dis. 2003; 188(5):625-34. DOI: 10.1086/377311. View

Higgins J, Thompson S, Deeks J, Altman D . Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60. PMC: 192859. DOI: 10.1136/bmj.327.7414.557. View

Sethi A, Celentano D, Gange S, Moore R, Gallant J . Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis. 2003; 37(8):1112-8. DOI: 10.1086/378301. View

Zeldin R, Petruschke R . Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother. 2003; 53(1):4-9. DOI: 10.1093/jac/dkh029. View

Kirk O, Lundgren J, Pedersen C, Mathiesen L, Nielsen H, Katzenstein T . A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors. Antivir Ther. 2004; 8(6):595-602. View

van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B . Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet. 2004; 363(9417):1253-63. DOI: 10.1016/S0140-6736(04)15997-7. View

Orkin C, Stebbing J, Nelson M, Bower M, Johnson M, Mandalia S . A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study). J Antimicrob Chemother. 2004; 55(2):246-51. DOI: 10.1093/jac/dkh515. View

10.

Portilla J, Boix V, Garcia-Henarejos J, Llopis C, Martinez-Madrid O, Gimeno A . Quadruple-2 protease inhibitors (PI)-therapy does not accelerate viral decay and suppression in PI-naive HIV-1 infected patients with severe immunosuppression and high viral load as compared with standard triple therapy. Int J STD AIDS. 2005; 16(12):807-10. DOI: 10.1258/095646205774988082. View

11.

Moyle G, Higgs C, Teague A, Mandalia S, Nelson M, Johnson M . An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy. Antivir Ther. 2006; 11(1):73-8. View

12.

Yeni P, Cooper D, Aboulker J, Babiker A, Carey D, Darbyshire J . Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial. Lancet. 2006; 368(9532):287-98. DOI: 10.1016/S0140-6736(06)69074-0. View

13.

Gulick R, Ribaudo H, Shikuma C, Lalama C, Schackman B, Meyer 3rd W . Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA. 2006; 296(7):769-81. DOI: 10.1001/jama.296.7.769. View

14.

. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008; 372(9635):293-9. PMC: 3130543. DOI: 10.1016/S0140-6736(08)61113-7. View

15.

Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009; 62(10):e1-34. DOI: 10.1016/j.jclinepi.2009.06.006. View

16.

Ciaranello A, Chang Y, Margulis A, Bernstein A, Bassett I, Losina E . Effectiveness of pediatric antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. Clin Infect Dis. 2009; 49(12):1915-27. PMC: 2787758. DOI: 10.1086/648079. View

17.

Montaner J, Lima V, Barrios R, Yip B, Wood E, Kerr T . Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet. 2010; 376(9740):532-9. PMC: 2996043. DOI: 10.1016/S0140-6736(10)60936-1. View

18.

Nachega J, Marconi V, van Zyl G, Gardner E, Preiser W, Hong S . HIV treatment adherence, drug resistance, virologic failure: evolving concepts. Infect Disord Drug Targets. 2011; 11(2):167-74. PMC: 5072419. DOI: 10.2174/187152611795589663. View

19.

Higgins J, Altman D, Gotzsche P, Juni P, Moher D, Oxman A . The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343:d5928. PMC: 3196245. DOI: 10.1136/bmj.d5928. View

20.

Joly V, Fagard C, Grondin C, Descamps D, Yazdanpanah Y, Charpentier C . Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: results of a randomized multicenter trial (ANRS 130 Apollo). Antimicrob Agents Chemother. 2012; 57(2):758-65. PMC: 3553717. DOI: 10.1128/AAC.01662-12. View